The company reported its highest-ever quarterly revenue of over INR 7,000 crore, with an impressive EBITDA margin of 28.1%.

Financial Highlights:

• Revenue from Operations: Cipla’s revenue for Q3 FY25 stood at INR 7,073 crore, marking an 8% year-on-year (YoY) growth. Excluding the divested QCIL business, the growth was 7% YoY.
• EBITDA: The company’s EBITDA surged to INR 1,989 crore, a 16% increase YoY, with the EBITDA margin expanding to 28.1%, up by 184 basis points compared to the same quarter last year.
• Profit After Tax (PAT): PAT witnessed a remarkable 50% YoY growth, reaching INR 1,571 crore, driven by operational efficiencies and a favorable product mix.

Key Business Highlights:

1. One-India Business:

Cipla’s domestic business continued to perform strongly, with a 10% YoY growth. The Branded Prescription segment outpaced market growth in key therapies such as Respiratory, Urology, and Acute. The Trade Generics business returned to a growth trajectory, supported by new product launches and technological interventions. Additionally, Cipla’s Consumer Health division maintained its leadership position with anchor brands like Nicotex, Omnigel, and Cipladine.

2. North America:

The North American market contributed $226 million in revenue for the quarter. Despite facing supply challenges with Lanreotide, the business was bolstered by strong performance in differentiated assets. Albuterol, a key generic product, ranked No. 1 in the U.S. market with a 21% market share. Cipla also received several generic drug approvals, including Phytonadione Injectable and Esomeprazole granules, further strengthening its portfolio.

3. One Africa:

Cipla’s African operations recorded a 9% YoY growth in USD terms, driven by strong performance in South Africa, where the company maintained its No. 1 position in the prescription market. The private market segment grew by 8.8%, significantly outpacing the overall market growth of 2%. New product launches and growth in the over-the-counter (OTC) portfolio also contributed to this success.

4. Emerging Markets and Europe:

The Emerging Markets and Europe segment posted a substantial 20% YoY growth in USD terms, supported by a deep market focus strategy. Both the Direct-to-Market (DTM) and Business-to-Business (B2B) categories showed strong performance, contributing to sustained margins.

R&D and Financial Health:

Cipla continued to invest in research and development (R&D), with Q3 FY25 R&D expenditures amounting to INR 360 crore, or 5.1% of sales. The company’s strong financial position was evident with a net cash balance of INR 8,947 crore, providing ample liquidity to support future growth initiatives.

Management Commentary:

Umang Vohra, MD and Global CEO of Cipla, expressed satisfaction with the company’s performance, stating, “We continue to make considerable progress across our focused markets. Despite supply challenges in the U.S., we delivered growth across all geographies, achieving our highest-ever EBITDA margin of 28.1%. Our One-India business grew at a healthy 10%, and our differentiated assets drove strong performance in North America. South Africa and Emerging Markets also delivered robust growth. Going forward, we will focus on growing our key markets, building our flagship brands, and investing in our future pipeline.”

Outlook:

Cipla’s strong Q3 FY25 performance underscores its ability to navigate market challenges while capitalizing on growth opportunities. The company’s focus on differentiated assets, market expansion, and operational efficiency positions it well for sustained growth in the coming quarters. With a robust pipeline and a strong balance sheet, Cipla is poised to continue its trajectory of delivering value to patients and shareholders alike.

Conclusion:

Cipla’s Q3 FY25 results reflect a company in strong financial health, with record revenues and profitability. The company’s strategic focus on key markets, coupled with its commitment to innovation and operational excellence, has enabled it to deliver consistent growth. As Cipla continues to expand its global footprint and strengthen its product portfolio, it remains a key player in the global pharmaceutical industry.

About Cipla Ltd:

Established in 1935, Cipla is a global pharmaceutical company with a strong presence in India, South Africa, North America, and other key markets. Known for its leadership in respiratory, anti-retroviral, and urology therapies, Cipla operates 46 manufacturing sites worldwide and serves over 80 markets. The company is committed to its purpose of “Caring for Life” and continues to make healthcare accessible and affordable for patients globally.